Intellectual Property Watch reports on a roundtable on global health law, innovation, access and justice, hosted last week by the Geneva-based Graduate Institute of International and Development Studies and Georgetown Law School. “At issue is the capacity of the pharmaceutical industry to innovate, and the potential barriers to access in a context of widespread diseases that blur the boundaries between developed and developing countries,” the news service writes, noting, “Most panelists concluded that governments should hold primary responsibility for the health of their populations” (Saez, 10/15).